- Research Article
- Open Access
Celecoxib increases retinoid sensitivity in human colon cancer cell lines
Cellular & Molecular Biology Lettersvolume 15, pages440–450 (2010)
Retinoid resistance has limited the clinical application of retinoids as differentiation-inducing and apoptosis-inducing drugs. This study was designed to investigate whether celecoxib, a selective COX-2 inhibitor, has effects on retinoid sensitivity in human colon cancer cell lines, and to determine the possible mechanism of said effects. Cell viability was measured using the MTT assay. Apoptosis was detected via Annexin-V/PI staining and the flow cytometry assay. PGE2 production was measured with the ELISA assay. The expression of RARβ was assayed via western blotting. The results showed that celecoxib enhanced the inhibitory effect of ATRA in both COX-2 high-expressing HT-29 and COX-2 low-expressing SW480 cell lines. Further study showed the ATRA and celecoxib combination induced greater apoptosis, but that the addition of PGE2 did not affect the enhanced growth-inhibitory and apoptosis-inducing effects of the combination. Moreover, NS398 (another selective COX-2 inhibitor) did not affect the inhibitory effects of ATRA in the two cell lines. Western blotting showed that the expression of RARβ in HT-29 cell lines was increased by celecoxib, but not by NS398, and that the addition of PGE2 did not affect the celecoxib-induced expression of the retinoic acid receptor beta. In conclusion, celecoxib increased the expression of RARβ and the level of cellular ATRA sensitivity through COX-2-independent mechanisms. This finding may provide a potential strategy for combination therapy.
all-trans retinoic acid
methyl thiazolyl tetrazolium
- PGE2 :
retinoic acid receptor beta
Weitz, J., Koch, M., Debus, J., Hohler, T., Galle, P.R. and Buchler, M.W. Colorectal cancer. Lancet 365 (2005) 153–165.
Sabharwal, A. and Kerr, D. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Rev. Anticancer Ther. 7 (2007) 477–487.
Gudas, L.J., Sporn, M.B. and Roberts, A.B. Cellular biology and biochemistry of the retinoids. in: The retinoids: Biology, Chemistry, and Medicine (Sporn, M.B., Roberts, A.B. and Goodman, D.S., Eds.), 2nd edition, Raven Press, New York, 1994, 443–520.
Xu, X.C. Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett. 253 (2007) 14–24.
Lee, M.O., Han, S.Y., Jiang, S., Park, J.H. and Kim, S.J. Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta. Biochem. Pharmacol. 59 (2000) 485–496.
van Zandwijk, N., Dalesio, O., Pastorino, U., de Vries, N. and van Tinteren, H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J. Natl. Cancer Inst. 92 (2000) 977–986.
Khuri, F.R., Lee, J.J., Lippman, S.M., Kim, E.S., Cooper, J.S., Benner, S.E., Winn, R., Pajak, T.F., Williams, B., Shenouda, G., Hodson, I., Fu, K., Shin, D.M., Vokes, E.E., Feng, L., Goepfert, H. and Hong, W.K. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J. Natl. Cancer Inst. 98 (2006) 441–450.
Koki, A.T., Leahy, K.M. and Masferrer, J.L. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin. Investig. Drugs. 8 (1999) 1623–1638.
Rostom, A., Dube, C., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M. and Moher, D. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann. Intern. Med. 146 (2007) 376–389.
Simeone, A.M., Li, Y.J., Broemeling, L.D., Johnson, M.M., Tuna, M. and Tari, A.M. Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells. Cancer Res. 64 (2004) 1224–1228.
Tari, A.M., Simeone, A.M., Li, Y.J., Gutierrez-Puente, Y., Lai, S. and Symmans, W.F. Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells. Lab. Invest. 85 (2005) 1357–1367.
Schroeder, C.P., Kadara, H., Lotan, D., Woo, J.K., Lee, H.Y., Hong, W.K. and Lotan, R. Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells. Cancer Res. 66 (2006) 9762–9770.
Li, M., Song, S., Lippman, S.M., Zhang, X.K., Liu, X., Lotan, R. and Xu, X.C. Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells. Oncogene 21 (2002) 411–418.
Song, S., Lippman, S.M., Zou, Y., Ye, X., Ajani, J.A. and Xu, X.C. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. Oncogene 24 (2005) 8268–8276.
Delage, B., Bairras, C., Buaud, B., Pallet, V. and Cassand, P. A high-fat diet generates alterations in nuclear receptor expression: prevention by vitamin A and links with cyclooxygenase-2 and beta-catenin. Int. J. Cancer. 116 (2005) 839–846.
Mernitz, H., Smith, D.E., Zhu, A.X. and Wang, X.D. 9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2. Cancer Lett. 244 (2006) 101–108.
Freemantle, S.J., Spinella, M.J. and Dmitrovsky, E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 22 (2003) 7305–7315.
Yamazaki, R., Kusunoki, N., Matsuzaki, T., Hashimoto, S. and Kawai, S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 531 (2002) 278–284.
Williams, C.S., Watson, A.J., Sheng, H., Helou, R., Shao, J. and DuBois, R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60 (2000) 6045–6051.
Niederberger, E., Tegeder, I., Vetter, G., Schmidtko, A., Schmidt, H., Euchenhofer, C., Brautigam, L., Grosch, S. and Geisslinger, G. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NFkappaB. FASEB J. 15 (2001) 1622–1624.
Zrieki, A., Farinotti, R. and Buyse, M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm. Res. 25 (2008) 1991–2001.
Sulova, Z., Macejova, D., Seres, M., Sedlak, J., Brtko, J. and Breier, A. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity. Toxicol. In Vitro 22 (2008) 96–105.
Soprano, D.R., Qin, P. and Soprano, K.J. Retinoic acid receptors and cancers. Annu. Rev. Nutr. 24 (2004) 201–221.
Grosch, S., Maier, T.J., Schiffmann, S. and Geisslinger, G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 98 (2006) 736–747.
Maier, T.J., Schilling, K., Schmidt, R., Geisslinger, G. and Grosch, S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem. Pharmacol. 67 (2004) 1469–1478.
Lefebvre, B., Brand, C., Flajollet, S. and Lefebvre, P. Down-regulation of the tumor suppressor gene retinoic acid receptor beta2 through the phosphoinositide 3-kinase/Akt signaling pathway. Mol. Endocrinol. 20 (2006) 2109–2121.